Magnesium cation

Identification

Name
Magnesium cation
Accession Number
DB01378
Type
Small Molecule
Groups
Approved, Nutraceutical
Description

Magnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents.

Structure
Thumb
Synonyms
  • Magnesium ion
  • Magnesium, ion(Mg2+)
Categories
UNII
T6V3LHY838
CAS number
22537-22-0
Weight
Average: 24.305
Monoisotopic: 23.985041898
Chemical Formula
Mg
InChI Key
JLVVSXFLKOJNIY-UHFFFAOYSA-N
InChI
InChI=1S/Mg/q+2
IUPAC Name
magnesium(2+) ion
SMILES
[Mg++]

Pharmacology

Indication
Not Available
Associated Therapies
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
USodium/potassium-transporting ATPase subunit alpha-1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Nucleotide Sugars MetabolismMetabolic
Inositol MetabolismMetabolic
Steroid BiosynthesisMetabolic
Methionine MetabolismMetabolic
Pyrimidine MetabolismMetabolic
Aspartate MetabolismMetabolic
Glutamate MetabolismMetabolic
Ibandronate Action PathwayDrug action
Etodolac Action PathwayDrug action
Ibuprofen Action PathwayDrug action
Alendronate Action PathwayDrug action
Lovastatin Action PathwayDrug action
Zoledronate Action PathwayDrug action
Mefenamic Acid Action PathwayDrug action
Adenosine Deaminase DeficiencyDisease
AlkaptonuriaDisease
Ethylmalonic EncephalopathyDisease
GalactosemiaDisease
Molybdenum Cofactor DeficiencyDisease
Pyruvate Dehydrogenase Complex DeficiencyDisease
Dimethylglycine Dehydrogenase DeficiencyDisease
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase DeficiencyDisease
SarcosinemiaDisease
Betaxolol Action PathwayDrug action
Dopamine Activation of Neurological Reward SystemSignaling
Intracellular Signalling Through Adenosine Receptor A2b and AdenosineSignaling
Tocainide Action PathwayDrug action
HypermethioninemiaDisease
Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke DiseaseDisease
HomocarnosinosisDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Magnesium cation.
AclidiniumThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Aclidinium.
AgmatineThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Agmatine.
AlcuroniumThe therapeutic efficacy of Alcuronium can be increased when used in combination with Magnesium cation.
AlfentanilThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Alfentanil.
AlmasilateThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Almasilate.
AloglutamolThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Aloglutamol.
AlphacetylmethadolThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Alphacetylmethadol.
AlphaprodineThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Alphaprodine.
AluminiumThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Aluminium.
Food Interactions
Not Available

References

Synthesis Reference

David S. Thompson, John S. Prestley, Jr., Thomas E. Webb, "Aluminum-magnesium alloys sheet exhibiting improved properties for forming and method aspects of producing such sheet." U.S. Patent US4151013, issued 0000.

US4151013
General References
Not Available
External Links
Human Metabolome Database
HMDB0000547
KEGG Compound
C00305
PubChem Compound
888
PubChem Substance
46508750
ChemSpider
865
BindingDB
15
ChEBI
18420
Therapeutic Targets Database
DCL000876
PharmGKB
PA164712884
HET
MG
Wikipedia
Magnesium
AHFS Codes
  • 88:29.00* — Minerals
  • 88:28.00 — Multivitamin Preparations
PDB Entries
101d / 109d / 119d / 121p / 13pk / 146d / 150d / 159d / 184d / 1a05
show 14035 more
MSDS
Download (73.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionOsteoporosis1
1CompletedPreventionPaclitaxel-induced Neuropathy1
1, 2CompletedSupportive CareHigh Blood Pressure (Hypertension) / Pre-Hypertension1
1, 2CompletedTreatmentTemporomandibular Joint Disorders1
1, 2Not Yet RecruitingTreatmentArterial Hypertension / Diabetes Mellitus (DM) / Hypokalaemia / Hyponatremias1
2CompletedPreventionNoise Induced Hearing Loss1
2CompletedPreventionPremature Atrial Contraction1
2CompletedSupportive CareIdiopathic Scoliosis1
2CompletedTreatmentAsthma Bronchial1
2CompletedTreatmentCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Neurologic Manifestations1
2CompletedTreatmentDelayed Onset Muscle Soreness, DOMS1
2CompletedTreatmentIntubation Conditions1
2CompletedTreatmentScoliosis1
2Not Yet RecruitingPreventionNeuropathic Pain Induced by Mastectomy1
2Not Yet RecruitingTreatmentChronic Kidney Disease (CKD) / Dialysis related complications / End Stage Renal Disease (ESRD)1
2Unknown StatusTreatmentAdenocarincoma of Pancreas / Stage III Pancreatic Cancer / Stage IVA Pancreatic Cancer / Stage IVB Pancreatic Cancer1
2, 3CompletedTreatmentPain NOS1
2, 3CompletedTreatmentPostoperative pain1
3CompletedTreatmentCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Infarction / Myocardial Ischemia1
3CompletedTreatmentNeoplasms, Colorectal1
3Not Yet RecruitingTreatmentCervical Cancers1
3Not Yet RecruitingTreatmentThrombotic Thrombocytopenic Purpura (TTP)1
3RecruitingPreventionExtreme Immaturity / Magnesium Deficiency / Premature Births1
3RecruitingTreatmentAlcohol Withdrawal Syndrome(AWS)1
3RecruitingTreatmentICSI1
3TerminatedTreatmentCoronary Artery Disease / Valvular Heart Disease1
3TerminatedTreatmentPremature Labour1
3TerminatedTreatmentRadiation-induced Oesophagitis1
4CompletedPreventionIntracranial Hemorrhages / Ischemia, Brain / Periventricular Leukomalacia / Premature Births1
4CompletedPreventionLiving Donor Liver Transplantation / Reperfusion Injury1
4CompletedTreatmentAlcohol-Induced Disorders1
4CompletedTreatmentHyperemesis Gravidarum / Morning Sickness / Nausea / Pregnancy / Vomiting1
4CompletedTreatmentAdjunct to general anesthesia therapy / Intravenous Anesthesia1
4CompletedTreatmentPatient With Neuropathic Pain1
4CompletedTreatmentPostoperative pain1
4CompletedTreatmentPre-eclampsia Aggravated1
4CompletedTreatmentPregnancy1
4RecruitingPreventionAcute Kidney Injury (AKI)1
4RecruitingPreventionPain in Pediatric Patients1
4RecruitingTreatmentDeep Neuromuscular Blockade / Magnesium Sulfate / Neuromuscular Blockade / Rocuronium1
4TerminatedSupportive CareArthritis Knee / Dexmedetomidine / Magnesium Sulfate1
4TerminatedTreatmentMagnesium Sulphate / Pain NOS / Post Pulmonary Resection1
Not AvailableCompletedNot AvailableThyroid Cancers1
Not AvailableCompletedOtherTherapeutic Opioid Induced Constipation (Disorder)1
Not AvailableCompletedPreventionEmergence Delirium1
Not AvailableCompletedPreventionHypomagnesaemia1
Not AvailableCompletedPreventionNonvalvular Atrial Fibrillation1
Not AvailableCompletedPreventionPostoperative pain1
Not AvailableCompletedTreatmentAsthma Bronchial1
Not AvailableNot Yet RecruitingNot AvailableMagnesium Therapy on Cerebral Palsy Patients1
Not AvailableTerminatedTreatmentPrimary Hypomagnesemia (Disorder)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • American Regent
  • American Therapeutics Medicines Inc.
  • Bioniche Pharma
  • Claris Lifesciences Inc.
  • DSM Corp.
  • Luitpold Pharmaceuticals Inc.
  • Mallinckrodt Baker Inc.
  • McGuff Co. Inc.
  • Merit Pharmaceuticals
  • Pekana Naturheilmittel GmbH
  • Torrance Co.
  • United Guardian Inc.
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)651 °CPhysProp
boiling point (°C)1100 °CPhysProp
Predicted Properties
PropertyValueSource
logP-0.57ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8382
Blood Brain Barrier+0.9708
Caco-2 permeable+0.7056
P-glycoprotein substrateNon-substrate0.8831
P-glycoprotein inhibitor INon-inhibitor0.9869
P-glycoprotein inhibitor IINon-inhibitor0.9855
Renal organic cation transporterNon-inhibitor0.9176
CYP450 2C9 substrateNon-substrate0.8465
CYP450 2D6 substrateNon-substrate0.823
CYP450 3A4 substrateNon-substrate0.8094
CYP450 1A2 substrateNon-inhibitor0.8824
CYP450 2C9 inhibitorNon-inhibitor0.9221
CYP450 2D6 inhibitorNon-inhibitor0.9555
CYP450 2C19 inhibitorNon-inhibitor0.9469
CYP450 3A4 inhibitorNon-inhibitor0.9846
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9015
Ames testNon AMES toxic0.9663
CarcinogenicityCarcinogens 0.6381
BiodegradationReady biodegradable0.9031
Rat acute toxicity2.0881 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.9716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as homogeneous alkaline earth metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a alkaline earth metal atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous alkaline earth metal compounds
Sub Class
Not Available
Direct Parent
Homogeneous alkaline earth metal compounds
Alternative Parents
Not Available
Substituents
Homogeneous alkaline earth metal
Molecular Framework
Not Available
External Descriptors
monoatomic dication, divalent metal cation, magnesium cation (CHEBI:18420) / a cation (MG+2)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Buchachenko AL, Kuznetsov DA, Berdinskii VL: [New mechanisms of biological effects of electromagnetic fields]. Biofizika. 2006 May-Jun;51(3):545-52. [PubMed:16808357]
  2. Sirijovski N, Olsson U, Lundqvist J, Al-Karadaghi S, Willows RD, Hansson M: ATPase activity associated with the magnesium chelatase H-subunit of the chlorophyll biosynthetic pathway is an artefact. Biochem J. 2006 Dec 15;400(3):477-84. [PubMed:16928192]
  3. Balasubramaniyan V, Nalini N: Leptin alters brain adenosine triphosphatase activity in ethanol-mediated neurotoxicity in mice. Singapore Med J. 2006 Oct;47(10):864-8. [PubMed:16990961]
  4. Nogovitsina OR, Levitina EV: Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Behav Physiol. 2007 Mar;37(3):199-202. [PubMed:17294093]

Drug created on July 06, 2007 14:30 / Updated on December 10, 2018 13:39